933785-18-3

Basic information

• Product Name: Ethyl 4-bromo-2-(trifluoromethoxy)benzoate
• Synonyms: Ethyl 4-bromo-2-(trifluoromethoxy)benzoate;4-Bromo-2-(trifluoromethoxy)benzoic acid methyl ester;2- trifluoromethoxy-4-bromobenzoate;Methyl 4-bromo-2-(trifluoromethoxy)
• CAS NO: 933785-18-3
• Molecular Formula: C₉H₆BrF₃O₃
• Molecular Weight: 299.041
• EINECS: 1533716-785-6
• Mol File: 933785-18-3.mol

Chemical Properties

• Boiling Point: 266℃
• Flash Point: 115℃
• Appearance: /
• Density: 1.626
• Vapor Pressure: 0.0089mmHg at 25°C
• Refractive Index: 1.486
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Ethyl 4-bromo-2-(trifluoromethoxy)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4-bromo-2-(trifluoromethoxy)benzoate(933785-18-3)
• EPA Substance Registry System: Ethyl 4-bromo-2-(trifluoromethoxy)benzoate(933785-18-3)

Safety Data

• Hazardous Substances Data: 933785-18-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Ethyl 4-bromo-2-(trifluoromethoxy)benzoate is used as a reagent in organic synthesis for the creation of various pharmaceutical compounds. Its unique structure and properties make it a valuable component in the synthesis process.
Used in Pharmaceutical Research:
In pharmaceutical research, Ethyl 4-bromo-2-(trifluoromethoxy)benzoate serves as a key intermediate, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Production:
Ethyl 4-bromo-2-(trifluoromethoxy)benzoate is utilized in the production of agrochemicals, where it plays a role in the formulation of products designed to protect crops and enhance agricultural yields.
Used in Dyes and Pigments Industry:
Ethyl 4-bromo-2-(trifluoromethoxy)benzoate also acts as an intermediate in the manufacture of dyes and pigments, contributing to the coloration and stability of various products in this industry.

InChI:InChI=1/C9H6BrF3O3/c1-15-8(14)6-3-2-5(10)4-7(6)16-9(11,12)13/h2-4H,1H3

Upstream product

• 201230-82-2 carbon monoxide 
• 67-56-1 methanol 
• 509142-48-7 4-bromo-2-(trifluoromethoxy)benzoic acid 

Downstream Products

• 509142-48-7 4-bromo-2-(trifluoromethoxy)benzoic acid 
• 1242145-45-4 4-(4-methoxycarbonyl)-3-(trifluoromethoxy)phenylboronic acid 
• 1242145-44-3 methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)-2-(trifluoromethoxy)benzoate 

Relevant articles and documents

5-ALKYNYL-PYRIMIDINES

The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

Discovery of (3 S,3a R)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5- tetrahydro-2 H -benzo[ g ]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy

We have discovered a novel class of nonsteroidal pyrazoline antagonists of the mineralocorticoid receptor (MR) that show excellent potency and selectivity against other nuclear receptors. Early analogues were poorly soluble and had a propensity to inhibit the hERG channel. Remarkably, both of these challenges were overcome by incorporation of a single carboxylate moiety. Structural modification of carboxylate-containing lead R-4g with a wide range of substituents at each position of the pyrazoline ring resulted in R-12o, which shows excellent activity against MR and reasonable pharmacokinetic profile. Introduction of conformational restriction led to a novel series characterized by exquisite potency and favorable steroid receptor selectivity and pharmacokinetic profile. Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection. As a result of these findings, 3S,3aR-27d was advanced to clinical studies.

NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE

The present invention relates to use of compounds of formula (I) as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation and new intermediates used therein, as pharmaceutical ingredients fo